The article emphasizes the rising popularity of GLP-1 receptor agonists for weight management in the UK, such as semaglutide and tirzepatide. It cautions that many individuals do not declare these medications when purchasing travel insurance, leading to the potential for claim denial and significant medical costs abroad. Experts, including Niraj Mamtora from Forum Insurance, stress the importance of transparency concerning medications to avoid severe financial consequences associated with non-disclosure during travel.
Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications.
Failure to declare your medication is not a minor oversight - it's a serious breach of your travel insurance contract.
Collection
[
|
...
]